DG,
Thanks for the constant effort to stay informed and share with the rest of us.
This post may be the most significant positive news yet.
RVL

I think shares were sold by management in collusion with someone standing on the "Grassy Knoll".................Geez

There has been quite a bit of controversy regarding using Vitaros for Raynaud's. Was any one on this Board aware of the fact that Apricus had IND with FDA ?
I was not.
RVL

This is from call:
"Turning to our progress on the pipeline front, earlier today we announced the significant milestone for Apricus. During the first quarter we submitted an investigational new drug or IND application to the FDA begin clinical testing with our internally development product candidate RayVa, for the treatment Raynaud's phenomenon secondary to scleroderma. Last week the FDA accepted our IND for RayVa, which clears the path for Apricus to being a Phase 2a trial in patients suffering from secondary Raynaud's phenomenon."

Sells at $2.00, Buys at $2.56
Other than feeble attempts at manipulation, anyone have insight?
RVL

JSB,
Are you guessing?
Or do you have any insight the rest of us don't have.
RVL

Amazing swing in opinion
Here is post from 4/28/14, 6 days ago

"I'm a buyer this morning. Not a big buyer but a buyer none the less.

My gut says you want to be in before the Q1 conference call."

Sorry, JoeBlack, I do think first script is 30 days. Although I do hope you are right and I am wrong.

I would suspect first script will always be for 30 days to allow physician to assess response/side effects. Thereafter, Prescriptions will be for either 30 days or 90 days depending on insurance company or PHarmacy Benefits manager and patient preference.

Carl Icahn/Apple vs. ????/Apricus

I call bottom. PPS up from here

Dave,
I received a call last week.
It has happened to me before....But not often
RVL

Thank you.....a rational perspective

I am as disappointed as anyone who has invested and stayed in this stock for 1+ years. What doesn't make sense is to be an investor, on this or any other board, and espouse a negative perspective on the future of the stock and/or a constant negative rant on management.
There can only be one reason to spend as much time typing opinions about a company night and day with a negative view.
There are many companies I believe are terrible investments, but I don't spend an instant telling others who have invested why they are wrong and I am right.
Life is too short.
RVL

Under cover?

Casino..
Actually it's the first day.
If you are going to bash use issues that are based on opinion.
From the website...........

The Very Best of International Urology
The Annual EAU Congress is a platform for the international urological community to share the latest and the most relevant knowledge with medical experts practising across the board.

Europe’s largest, this urology event annually gathers thousands of delegates and exhibitors from over 100 countries. More than 14,000 visitors are expected to attend the 29th Annual EAU Congress in Stockholm on 11-15 April 2014.
RVL

Anyone have access to this.......??



LONDON, Apr 11, 2014 (PR Newswire Europe via COMTEX) -- LONDON, April 11, 2014 /PRNewswire/ --

Needle-free delivery - discover technological and commercial prospects

What does the future hold for the needle-free delivery market [ https://www.visiongain.com/Report/1236/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024 ] ? Visiongain [ https://www.visiongain.com ]'s brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 187 page report provides 103 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

Binchey,
I know you follow and are well informed about a number of Biotech stocks. Since it appears that Biotechs have been crushed and are going to continue to take a beating over the short term. Where does APRI fit compared to the other Biotechs you follow since Jan 1?
Is this just the tide going out for Biotechs or is this drop in PPS an APRI issue?
RVL

Value, you are right of the 25-30 tech/pharma stocks I am following APRI is only that is Green

Just throw stuff at the wall

Shazam,

Let em go on with comments.
I have finally decided to not get too disturbed by the rant regarding management/board and the; we know better, off with their heads, make them accountable, rhetoric

I have been adding to position the last few times PPS was driven down.
This time the dip in market has taken it even lower.

We know we're going back up.

Thanks for your efforts Beach and Social. I am on board with the tactic.

RVL

I may be clueless, but I am self aware.
I don't have the delusion that I can behave as if I am Carl Icahn. This is a Biotech stock with a product that works, that has been poorly managed for the last few years.
We'll see.

Good luck.
RVL

I think the issue is, if you don't like actions of management, direction of stock, etc. SELL!
To think the participants on this Board can impact (or force) the strategic decisions that the Board & Management makes is not worth stressing out over. We are bit players.
Educate yourself, observe actions of management. If you don't like it, SELL!

Life is too short.

I am speculating, or maybe just hopeful, but based on timing of April 11-European Urology meeting prepping major group of potential prescribers, and upcoming annual APRI stockholder meeting in May where Executive compensation is an issue, I would, (if I were APRI management)
1. announce or even implement Vitaros launch between meetings.
OR
2. announce acquisition of Vitaros US rights
OR
3. Femprox worldwide partnership.

If none of those events occur in advance of May APRI shareholder meeting, it's not the end of the world, but management has an lost an opportunity for themselves.

RVL

Is anyone out there tracking this in Stockholm on Friday, 11 April 2014, ?

A new paradigm in the treatment of ED - the topical option


29th Annual EAU Congress from 11 to 15 April 2014. Considered as Europe’s biggest urology event , the meeting will present the latest developments in international urology with a comprehensive and extensive scientific programme.

Sponsored by APRICUS BIOSCIENCES
Chair J.P. Mulhall, New York (US)

16.15 - 16.35 Understanding the ED patient
Speaker Y. Reisman, Amstelveen (NL)

16.35 - 16.55 The clinical care pathway in the management of the ED patient
Speaker F. Giuliano, Garches (FR)

16.55 - 17.15 Vitaros: A novel strategy for ED management
Speaker E. Kim, Knoxville (US)

17.15 - 17.45 Case studies and discussions
Speaker J.P. Mulhall, New York (US)

Irina
Consider the source???

Irina Rivkind's Experience

Equity Research Analyst, Specialty Pharmaceuticals
Cantor Fitzgerald
Privately Held; 1001-5000 employees; Financial Services industry
October 2011 – Present (2 years 6 months) New York, New York

Senior Research Analyst
Duncan-Williams, Inc.
Privately Held; 51-200 employees; Investment Banking industry
March 2010 – November 2011 (1 year 9 months)

Equity research analyst focusing on specialty pharmaceuticals
Assoc. Analyst
UBS
Public Company; 10,001+ employees; UBS; Financial Services industry
October 2006 – March 2010 (3 years 6 months)

Sell side equity research, with a focus on healthcare, specifically towards specialty pharmaceuticals.
Product Manager
Forest Laboratories
Public Company; 5001-10,000 employees; FRX; Pharmaceuticals industry
2001 – 2006 (5 years)

Irina Rivkind's Skills & Expertise

Equity Research Equities Valuation Healthcare Bloomberg Private Equity Mergers & Acquisitions Capital Markets Investment Banking
Irina Rivkind's Education

New York University - Leonard N. Stern School of Business
MBA
2001 – 2004

University of Maryland Baltimore
MS, Epidemiology and Preventive Medicine
1999 – 2000

Cornell University
BA, Biology
1992 – 1996

Great,
FINALLY looks like we're serious about Femprox

NEPT Bloomberg article "Foods Rich in Omega-3 May Not Protect Heart, Study Finds"
Permanent decrease in demand for krill oil and drop in PPS ?

Interestingly, when there actually is news that is positive, some of the frequent posters here totally stop.

RECORDATI looks to be a strong growing company:

BOARD APPROVES THE 2013 ACCOUNTS.

MILANO, Italy, March 6, 2014 (GLOBE NEWSWIRE) -- RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS. REVENUE EUR 941.6 MILLION (+13.7%), OPERATING INCOME EUR 195.4 MILLION (+17.0%), NET INCOME EUR 133.7 MILLION (+12.8%). 2013 DIVIDEND EUR 0.33 (+10.0%).

-- Consolidated revenue EUR 941.6 million, + 13.7%.

-- EBITDA(1) EUR 230.1 million, + 20.0%

-- Operating income EUR 195.4 million, + 17.0%.

-- Net income EUR 133.7 million, + 12.8%.

-- Net financial position(2): net debt of EUR 261.0 million.

-- Dividend for 2013 EUR 0.33 per share, of which EUR 0.22 already paid.

-- Targets for 2014: sales to exceed EUR 1,000 million, operating to exceed
EUR 220 million and net income to exceed EUR 150 million.

Social,
Holding management accountable and the resulting lack of popularity is not the issue.
The issue is:
"You can't have it both ways.
You put no credibility behind management statements when they are defining progress toward goals. Then in other statements you make, you demand that they hit the goals that they state or they need go."

You are either purposefully trying to adversely influence people on the iHub board or a shareholder that is impossible to please.
(Ie. glass is half empty)
Success will be the result of product sales.
There is little we "normal" investors can do to influence management or PPS. (Other than post overly optimistic or pessimistic opinions for a thinly traded stock and hope the herd reacts)
We, as "normal" investors, can do research and stay up to date with direct and indirect opportunities and threats and adapt.
But....If you are a long investor and you don't believe in product or management, sell your shares and move on. That's what I will do. There are other stocks to invest in. That is why I find it hard to believe your posts are sincere and are most likely an attempt to influence others.
The only reason I post is I am tired of your methodical efforts.
Rvl

Ok, we'll see.
I believe you have quite a few skeptics regarding motives.

Social,
You can't have it both ways.
You put no credibility behind management statements when they are defining progress toward goals. Then in other statements you make, you demand that they hit the goals that they state or they need go.

I will state this again and likely my post will be removed. If I review all of your posts since you recently arrived on the iHub board, you do not sound like someone who invested or would still own shares with the perspectives you put forward. If you are one of the former folks, Courtfool, et.al. I applaud your improved tactics with frequent posts of positive yet very concerned, somewhat informed opinions alternating with subtle negativity to overtly negative. This appears to have more people on the board believing you have good intentions. I invite others to review your posts.
Rvl

Social,
I just don't believe anyone that owns a reasonable amount of stock (less than $1M) really can not impact actions of management. Management knows more about the information that we are by definition not privy to, determines a course of action under direction of board and the outcome occurs.
I actually don't want them to listen to a single shareholder or a group of observers on the internet. I want them to focus on task at hand. If I don't have confidence or worse yet they fail, I am out. Similarly, I will never go back to a restaurant that fails me. I leave and tell others not to go there.
Rvl

Ok, I will understand.
My major difference of opinion is that, despite the fact I own a fair bit of APRI, I do not view myself as employer, or part of governance, but merely an observer.
Therefore, I can not alter the course of a stock price over a long period of time, I can merely educate myself stay current and buy low and sell high.
RVL

SocialBoom,
As you point out, this is not a personal attack and I trust this post will not be removed by the moderator. I have a question.

In reviewing the 39 posts you have had since your first on 2/11/14, you have been consistent with your pessimistic view of product & management. For me, I do not follow any Board and involve myself in debates with members of Boards for companies I do not believe are good investments. Nor, do I try to spread my opinion to the members of those boards to influence them. I am too busy.
My question to you is, what is your purpose in participating on this Board? To save us from a bad investment, educate us? Rally us to hold management accountable?

There are those who obviously are too optimistic and pump with hope and no facts. I do not appreciate their obvious motives. You appear to be negative from the first post. Therefore, I question the time & effort you are putting into this Board and your motives.
RVL

Seekin Alpha article just out!

A appreciate the sentiment. That's why I haven't been near YMB for about a year. It's not the questions, it's the rant. Honest opinions are good. Facts are better. Purposeful bashing (or pumping) based on an obvious motivation to manipulate us has no place. Take a look at line of comments of the folks who post. If they are extreme in either direction, based on their feelings, opinions or a loose collection of selected facts, it will give you a hint at their motives.
Just look at their line of comments, judge for your self.
Rvl

I hope first launch is in France. They have drug and use injectable dosage form already. Conversion of current users to Vitaros should be about 100%. Therefore, very rapid launch.
In any event, Big pharma launch of this product will send PPS to the moon.

Casino,
Hey, nice one...
Mine is Abbott just bought APRI for $20 per share
Rvl

Was this meant to be a "Private" reply?